1.
Gematol Transfuziol
; 40(3): 6-8, 1995.
Article
in Russian
| MEDLINE
| ID: mdl-7642085
ABSTRACT
Immune status in relation to tumor progression was evaluated in 175 patients with chronic myeloproliferative diseases. 113 of them had chronic myeloid leukemia, 62 chronic subleukemic myelosis. It was established that immunologic reactivity decline correlated with the rate of tumor progression. The degree of immune deficiency should be taken into consideration in selection of patients for immunotherapy.